CHRS - Coherus BioSciences Inc. (CHRS) Q4 2023 Earnings Call Transcript
2024-03-13 20:56:10 ET
Coherus BioSciences, Inc. (CHRS)
Q4 2023 Results Conference Call
March 13, 2024 05:00 PM ET
Company Participants
Jamie Taylor - Head of Investor Relations
Dennis Lanfear - Chief Executive Officer
Paul Reider - Chief Commercial Officer
Rosh Dias - Chief Medical Officer
Theresa LaVallee - Chief Development Officer
Bryan McMichael - Interim Chief Financial Officer
Conference Call Participants
Yigal Nochomovitz - Citigroup
Colleen Kusy - Baird
Michael Nedelcovych - TD Cowen
Ethan Brown - JPMorgan
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q4 2023 Coherus BioSciences, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jamie Taylor, Head of Investor Relations for Coherus.
Jamie Taylor
Thank you, operator. Good afternoon, and welcome to Coherus BioSciences fourth quarter and full-year 2023 earnings conference call. Joining me today to discuss our results are Denny Lanfear, Chief Executive Officer of Coherus; Bryan McMichael, Interim Chief Financial Officer; Paul Reider, Chief Commercial Officer; Rosh Dias, Chief Medical Officer; and Theresa LaVallee, Chief Development Officer.
Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus’ current expectations about future events. These statements include, but are not limited to, the following: Our ability to advance our pipeline, projections of future growth, revenue, expenses, headcount, and debt levels, and the timing of any return to profitability or cash flow positivity. All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from those implied by the forward-looking statements....
Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript